13 March 2024
13 March 2024
The two trials will evaluate alternative dosing regimens for Gardasil 9 vaccine compared to the currently approved three-dose regimen.
As per the deal, Merck will supply KEYTRUDA to IDEAYA for the trial conduct while IDEAYA will sponsor the study.
The positive data was presented at the Cardiovascular Research Technologies (CRT) conference in Washington, DC.
Walking ability improved significantly in 16 patients after 12 months of treatment with NG-01.
The safety and efficacy of ICP-248 plus orelabrutinib against immunochemotherapy will be assessed in the trial.
ADCETRIS’ safety and tolerability profile in the trial was in line with prior data.
As the race for the first FDA-approved MASH treatment hots up, 89bio starts its Phase III trial, with another on the way soon.
In 2023, the incident cases of TB reached pre-pandemic levels in the UK, suggesting that prevention and infection control needs to be reconsidered.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
